JY-231

N/A

Report date: 2026/04/23 20:00:25

Base Information

Drug NameJY-231
Drug Alias NameJY-231JY231
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity
TargetsUpdating
Therapy Area/IndicationsAutoimmune DiseasesLupus Erythematosus, SystemicAutoimmune Diseases of the Nervous System +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShenzhen Genocury Biotech Ltd
China Registration ClassN/A

Develop Information

Active CompaniesThe Second People Hospital Of Guangdong ProvinceAffiliated Hospital Of Guangdong Medical UniversityThe First Affiliated Hospital Of Zhejiang University School Of Medicine +[6] 
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesLupus Erythematosus, SystemicAutoimmune Diseases of the Nervous System +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A